Merck’s diabetes powerhouse Januvia isn’t going anywhere in the face of stepped-up competition from Eli Lilly and Boehringer Ingelheim's standout Jardiance, the pharma giant has said. And that forecast held strong in Q2.
NEW ORLEANS--Merck & Co. and Pfizer are doubling down on their ertugliflozin cardiovascular outcomes study as rival SGLT-2 med Jardiance continues to generate buzz for its recent score in a heart-safety test.
Say goodbye to Merck's once-weekly DPP-4 diabetes candidate, omarigliptin. The company dropped development of the Phase III med, it said recently--and its heart-healthy rivals may have something to do with that.